News | August 19, 2024
CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
The emergence of new infections in India is a growing concern
The emergence of new infections in India is a growing concern
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Subscribe To Our Newsletter & Stay Updated
